ProCE Banner Series

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers

Interact with an expert during a 1-hour, CME/CE-certified live meeting examining recent advances and current best practices in biomarker-driven treatment for gastrointestinal cancers. Register today!

To Register:  Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for oncologists, nurses, pharmacists, and other healthcare professionals on the multidisciplinary team caring for patients with gastrointestinal cancers.

All Events

Past Events

July

25

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Private Event, Bennington, Vermont

July

27

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers

6:30 PM - 7:30 PM Eastern Time (ET)

In-personVirtual

Private Event | Host Group at Mark's Prime, Gainesville, Florida

August

19

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers

11:30 AM - 12:30 PM Eastern Time (ET)

In-personVirtual

Private Event | Host Group at Hilton, Daytona Beach, Florida

September

09

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers

1:00 PM - 2:00 PM Pacific Time (PT)

In-person

Private Event | Host Group at JW Marriott, Los Angeles, California

September

19

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers [Open Registration]

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MI, Royal Oak, Michigan

September

27

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers

6:00 PM - 7:00 PM Eastern Time (ET)

In-person

Private Event | Host Group in VA, Lansdowne, Virginia

October

01

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers

10:40 AM - 11:40 AM Central Time (CT)

In-person

Private Event | Host Group in Winfield, Winfield, Illinois

October

19

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers

7:30 AM - 8:30 AM Pacific Time (PT)

Virtual

Virtual Event | Host Group in Post Falls, Post Falls, Idaho

October

21

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers [Open Registration]

10:30 AM - 11:30 AM Pacific Time (PT)

In-person

Live Event | Host Group NV, Reno, Nevada

October

30

2023

Updates for Community Practice: Guidance on Biomarker-Driven Therapeutic Approaches in GI Cancers [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, Dallas, Texas

Topics

  • Histology-Agnostic Biomarkers in GI Malignancies
  • Biomarker-Driven Treatment of Advanced Colorectal Cancer
  • Biomarker-Driven Treatment of Gastric, Esophageal, Gastroesophageal Junction, Pancreatic, and Biliary Tract Cancers
  • Live Audience Question and Answer Session
 

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to assess new and emerging GI biomarkers and to integrate biomarker findings into the planning of individualized treatments for patients with gastrointestinal malignancies.

Target Audience
This educational program is intended for oncologists, nurses, pharmacists, and other healthcare professionals on the multidisciplinary team caring for patients with gastrointestinal cancers. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply best practices for molecular testing in GI cancers, including the use of tissue-based biomarker testing for evaluation of BRAF V600E, HER2, HER3, BRCA1/2, FGFR2, IDH1, and histology-agnostic markers
  • Discuss with patients the available clinical data and how predictive biomarkers can be used to guide therapy decisions in GI cancers
  • Plan individualized therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
  • Identify patients with GI malignancies who are appropriate for enrollment on ongoing clinical trials investigating novel biomarker-driven treatment strategies in GI malignancies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-175-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Merck Sharp & Dohme LLC.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191